IMMUNOHISTOCHEMICAL DISTRIBUTION OF C-ERBB-2 IN INSITU BREAST-CARCINOMA - A DETAILED MORPHOLOGICAL ANALYSIS

被引:118
|
作者
RAMACHANDRA, S
MACHIN, L
ASHLEY, S
MONAGHAN, P
GUSTERSON, BA
机构
[1] INST CANC RES,HADDOW LABS,CLIFTON AVE,SUTTON SM2 5NG,SURREY,ENGLAND
[2] ST GEORGE HOSP,SCH MED,LONDON SW17 0RE,ENGLAND
[3] ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND
关键词
breast carcinoma; c‐erbB‐2; immunohistochemistry; Oncogenes;
D O I
10.1002/path.1711610104
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An immunohistochemical study of c‐erbB‐2 expression was carried out on in situ (non‐invasive) breast carcinoma, using antibody 21N, raised to the intracytoplasmic domain of the c‐erbB‐2 oncogene product. Strong membrane staining was observed in 44 out of 74 (59 per cent) cases of ductal carcinoma in situ (DCIS), but none of 48 lobular carcinoma in situ (LCIS) lesions. A detailed comparative morphological evaluation using several different parameters, including histological subtypes, was performed within the DCIS group. The results showed that there was a significant correlation between c‐erbB‐2 expression and the presence of large cell size, periductal lymphoid cell infiltration, marked nuclear pleomorphism, multinucleation, and a high mitotic rate. Of these, cell size appears to be the most important predictor of c‐erbB‐2 status, followed by the presence of periductal lymphoid cell infiltration. These results indicate, firstly, that LCIS and DCIS are biologically (as well as histologically) different and, secondly, that a subgroup of DCIS, which is associated with c‐erbB‐2 over‐expression, exists and appears to have distinct histological features. The subgroup of DCIS cases which over‐express c‐erbB‐2 may be a biologically definable category with prognostic importance. These results may therefore have relevance to breast screening programmes, but a larger study incorporating clinical data would be necessary to correlate these findings with clinical outcome. Copyright © 1990 John Wiley & Sons, Ltd.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 50 条
  • [1] ESTROGEN AND PROGESTERONE-RECEPTOR AND C-ERBB-2 ONCOPROTEIN ANALYSIS IN PURE INSITU BREAST-CARCINOMA - AN IMMUNOHISTOCHEMICAL STUDY
    WILBUR, DC
    BARROWS, GH
    MODERN PATHOLOGY, 1993, 6 (02) : 114 - 120
  • [2] RELATIONSHIP BETWEEN C-ERBB-2 IMMUNOREACTIVITY AND THYMIDINE LABELING INDEX IN BREAST-CARCINOMA INSITU
    BARNES, DM
    MEYER, JS
    GONZALEZ, JG
    GULLICK, WJ
    MILLIS, RR
    BREAST CANCER RESEARCH AND TREATMENT, 1991, 18 (01) : 11 - 17
  • [3] C-ERBB-2 ONCOPROTEIN IS NOT AN INDEPENDENT PROGNOSTIC PARAMETER IN PRIMARY BREAST-CARCINOMA - AN IMMUNOHISTOCHEMICAL STUDY
    HAERSLEV, T
    JACOBSEN, GK
    APMIS, 1994, 102 (08) : 612 - 622
  • [4] INSITU DISTRIBUTION OF ONCOGENE PRODUCTS AND GROWTH-FACTOR RECEPTORS IN BREAST-CARCINOMA - C-ERBB-2 ONCOPROTEIN, EGFR, AND PDGFR-BETA-SUBUNIT
    KOMMOSS, F
    COLLEY, M
    HART, CE
    FRANKLIN, WA
    MOLECULAR AND CELLULAR PROBES, 1990, 4 (01) : 11 - 23
  • [5] EVALUATION OF C-ERBB-2 AMPLIFICATION IN BREAST-CARCINOMA BY DIFFERENTIAL POLYMERASE CHAIN-REACTION
    GRAMLICH, TL
    COHEN, C
    FRITSCH, C
    DEROSE, PB
    GANSLER, T
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1994, 101 (04) : 493 - 499
  • [6] NUCLEAR AND FLOW CYTOMETRIC CHARACTERISTICS ASSOCIATED WITH OVEREXPRESSION OF THE C-ERBB-2 ONCOPROTEIN IN BREAST-CARCINOMA
    POLLER, DN
    GALEA, M
    PEARSON, D
    BELL, J
    GULLICK, WJ
    ELSTON, CW
    BLAMEY, RW
    ELLIS, IO
    BREAST CANCER RESEARCH AND TREATMENT, 1991, 20 (01) : 3 - 10
  • [7] IMMUNOHISTOCHEMICAL STUDY ON THE EXPRESSION OF C-ERBB-2 ONCOPROTEIN IN BREAST-CANCER
    HORIGUCHI, J
    IINO, Y
    TAKEI, H
    YOKOE, T
    ISHIDA, T
    MORISHITA, Y
    ONCOLOGY, 1994, 51 (01) : 47 - 51
  • [8] EXPRESSION OF C-ERBB-2 IN INSITU AND IN ADJACENT INVASIVE DUCTAL ADENOCARCINOMAS OF THE FEMALE BREAST
    MAGUIRE, HC
    HELLMAN, ME
    GREENE, MI
    YEH, I
    PATHOBIOLOGY, 1992, 60 (03) : 117 - 121
  • [9] PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) AND C-ERBB-2 ONCOPROTEIN IN BREAST-CARCINOMA WITH CORRELATIONS TO HISTOPATHOLOGICAL PARAMETERS AND PROGNOSIS
    HAERSLEV, T
    JACOBSEN, GK
    ZEDELER, K
    ONCOLOGY REPORTS, 1995, 2 (01) : 99 - 105
  • [10] Serial serum c-erbB-2 levels in patients with breast carcinoma
    Volas, GH
    Leitzel, K
    Teramoto, Y
    Grossberg, H
    Demers, L
    Lipton, A
    CANCER, 1996, 78 (02) : 267 - 272